Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model

Dae-Jin Song, Jae Youn Cho, Marina Miller, Wendy Strangman, Mai Zhang, Ajit Varki, David H. Broide

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Siglec-F is a sialic acid binding immunoglobulin-superfamily receptor that is highly expressed on eosinophils. We have used a mouse model of oral egg ovalbumin (OVA)-induced eosinophilic inflammation of the gastro-intestinal mucosa associated with diarrhea and weight loss to determine whether administering an anti-Siglec-F antibody would reduce levels of intestinal mucosal eosinophilic inflammation. Mice administered the anti-Siglec-F antibody had significantly lower levels of intestinal eosinophilic inflammation, and this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain. The reduced numbers of intestinal eosinophils in anti-Siglec-F antibody treated mice was associated with significantly reduced numbers of bone marrow and peripheral blood eosinophils, but was not associated with significant changes in the numbers of proliferating or apoptotic jejunal eosinophils. In addition, the anti-Siglec-F Ab reduced Th2 cytokines and IgE levels. Overall, these studies demonstrate that administration of an anti-Siglec-F antibody significantly reduces levels of eosinophilic inflammation in the intestinal mucosa and that this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain.

Original languageEnglish
Pages (from-to)157-169
Number of pages13
JournalClinical Immunology
Volume131
Issue number1
DOIs
Publication statusPublished - 2009 Apr 1

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
Allergens
Ovum
Inflammation
Eosinophils
Antibodies
Intestinal Mucosa
Weight Gain
Permeability
Ovalbumin
N-Acetylneuraminic Acid
Immunoglobulin E
Immunoglobulins
Weight Loss
Diarrhea
Bone Marrow
Cytokines

Keywords

  • Eosinophils
  • Food allergy
  • Inflammation
  • Siglec-F

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. / Song, Dae-Jin; Cho, Jae Youn; Miller, Marina; Strangman, Wendy; Zhang, Mai; Varki, Ajit; Broide, David H.

In: Clinical Immunology, Vol. 131, No. 1, 01.04.2009, p. 157-169.

Research output: Contribution to journalArticle

Song, Dae-Jin ; Cho, Jae Youn ; Miller, Marina ; Strangman, Wendy ; Zhang, Mai ; Varki, Ajit ; Broide, David H. / Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model. In: Clinical Immunology. 2009 ; Vol. 131, No. 1. pp. 157-169.
@article{c1336d52668d48499888a559fad32eee,
title = "Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model",
abstract = "Siglec-F is a sialic acid binding immunoglobulin-superfamily receptor that is highly expressed on eosinophils. We have used a mouse model of oral egg ovalbumin (OVA)-induced eosinophilic inflammation of the gastro-intestinal mucosa associated with diarrhea and weight loss to determine whether administering an anti-Siglec-F antibody would reduce levels of intestinal mucosal eosinophilic inflammation. Mice administered the anti-Siglec-F antibody had significantly lower levels of intestinal eosinophilic inflammation, and this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain. The reduced numbers of intestinal eosinophils in anti-Siglec-F antibody treated mice was associated with significantly reduced numbers of bone marrow and peripheral blood eosinophils, but was not associated with significant changes in the numbers of proliferating or apoptotic jejunal eosinophils. In addition, the anti-Siglec-F Ab reduced Th2 cytokines and IgE levels. Overall, these studies demonstrate that administration of an anti-Siglec-F antibody significantly reduces levels of eosinophilic inflammation in the intestinal mucosa and that this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain.",
keywords = "Eosinophils, Food allergy, Inflammation, Siglec-F",
author = "Dae-Jin Song and Cho, {Jae Youn} and Marina Miller and Wendy Strangman and Mai Zhang and Ajit Varki and Broide, {David H.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1016/j.clim.2008.11.009",
language = "English",
volume = "131",
pages = "157--169",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model

AU - Song, Dae-Jin

AU - Cho, Jae Youn

AU - Miller, Marina

AU - Strangman, Wendy

AU - Zhang, Mai

AU - Varki, Ajit

AU - Broide, David H.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Siglec-F is a sialic acid binding immunoglobulin-superfamily receptor that is highly expressed on eosinophils. We have used a mouse model of oral egg ovalbumin (OVA)-induced eosinophilic inflammation of the gastro-intestinal mucosa associated with diarrhea and weight loss to determine whether administering an anti-Siglec-F antibody would reduce levels of intestinal mucosal eosinophilic inflammation. Mice administered the anti-Siglec-F antibody had significantly lower levels of intestinal eosinophilic inflammation, and this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain. The reduced numbers of intestinal eosinophils in anti-Siglec-F antibody treated mice was associated with significantly reduced numbers of bone marrow and peripheral blood eosinophils, but was not associated with significant changes in the numbers of proliferating or apoptotic jejunal eosinophils. In addition, the anti-Siglec-F Ab reduced Th2 cytokines and IgE levels. Overall, these studies demonstrate that administration of an anti-Siglec-F antibody significantly reduces levels of eosinophilic inflammation in the intestinal mucosa and that this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain.

AB - Siglec-F is a sialic acid binding immunoglobulin-superfamily receptor that is highly expressed on eosinophils. We have used a mouse model of oral egg ovalbumin (OVA)-induced eosinophilic inflammation of the gastro-intestinal mucosa associated with diarrhea and weight loss to determine whether administering an anti-Siglec-F antibody would reduce levels of intestinal mucosal eosinophilic inflammation. Mice administered the anti-Siglec-F antibody had significantly lower levels of intestinal eosinophilic inflammation, and this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain. The reduced numbers of intestinal eosinophils in anti-Siglec-F antibody treated mice was associated with significantly reduced numbers of bone marrow and peripheral blood eosinophils, but was not associated with significant changes in the numbers of proliferating or apoptotic jejunal eosinophils. In addition, the anti-Siglec-F Ab reduced Th2 cytokines and IgE levels. Overall, these studies demonstrate that administration of an anti-Siglec-F antibody significantly reduces levels of eosinophilic inflammation in the intestinal mucosa and that this was associated with reduced intestinal permeability changes, normalization of intestinal villous crypt height, and restoration of weight gain.

KW - Eosinophils

KW - Food allergy

KW - Inflammation

KW - Siglec-F

UR - http://www.scopus.com/inward/record.url?scp=63249123223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249123223&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2008.11.009

DO - 10.1016/j.clim.2008.11.009

M3 - Article

VL - 131

SP - 157

EP - 169

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -